Maxigen BiotechTPE:1783 -1.55%87 EBITDA Margin % is 66.81% as of Dec. 2025, which is 170% above its 10-year median of 24.79. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 816 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 97.18% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Maxigen Biotech's EBITDA for the
three
months ended in Dec. 2025 was NT$150.1 Mil. Maxigen Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$224.7 Mil. Therefore, Maxigen Biotech's EBITDA margin for the quarter that ended in Dec. 2025 was 66.81%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Maxigen Biotech EBITDA Margin % Related Terms
Maxigen Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a EBITDA Margin % of 66.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maxigen Biotech and its competitors. This is 170% above median its historical median of 24.79. Over the past decade, Maxigen Biotech's EBITDA Margin % has ranged from 3.26 to 41.53. According to the industry distribution chart, Maxigen Biotech ranks #23 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 2.8%.
Is Maxigen Biotech's EBITDA Margin % too high?
Maxigen Biotech's current EBITDA Margin % of 66.81% is 170% above median its 10-year median of 24.79. Over the past 10 years, this metric has ranged from a low of 3.26 to a high of 41.53. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Maxigen Biotech's value of 66.81% is 793.8% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #23 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #23 out of 816 companies for EBITDA Margin %. This places Maxigen Biotech in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Maxigen Biotech's value of 66.81% is 793.8% above this benchmark. Historically, Maxigen Biotech's own EBITDA Margin % has ranged from 3.26 to 41.53 over the past decade. While the company's 10-year median is 24.79 vs. the industry median of 7.48, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current EBITDA Margin % of 66.81% is 793.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current EBITDA Margin % is 66.81%, which is 170% above median its own 10-year median of 24.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current EBITDA Margin % is 66.81%, which is 170% above median its 10-year median of 24.79 and 793.8% above the Medical Devices & Instruments industry median of 7.48. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current EBITDA Margin % is 66.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
EBITDA Margin %: 66.81% (170% above median its 10-year median of 24.79)
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
Industry Position: 793.8% above the Medical Devices & Instruments median (#23 of 816)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
